Patents for A61P 35 - Antineoplastic agents (221,099)
12/2009
12/02/2009CN101591371A Method for preparing gemcitabine or analogues thereof through halogen-exchange fluorination
12/02/2009CN101591369A N-glycosyl-3-aryl acrylamide derivative, preparation method and medical function thereof
12/02/2009CN101591368A Girald pteroxygonum root neoflavonoid compound
12/02/2009CN101591364A Amino sugar derivative, preparation method thereof and medicinal application thereof
12/02/2009CN101591357A Group of phosphate/phosphate ester compounds for inhibiting BCR-ABL kinase
12/02/2009CN101591350A Group of boric acid/boric acid ester compounds for inhibiting BCR-ABL kinase
12/02/2009CN101591348A Tetrahydrochysene carboline acyl aminoacid benzyl ester, preparation method and application thereof
12/02/2009CN101591341A Alkyl porphyrin compound, preparation and application thereof in field of medicaments and pesticides
12/02/2009CN101591340A 5,10,15,20-tetra-(5-drewamine amyl)-chlorin, preparation and application thereof in field of medicaments and pesticides
12/02/2009CN101591335A N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof
12/02/2009CN101591332A Compound based on 4-phenyl-6-(2, 2, 2-trifluoro-1-phenylethoxy) pyridine and application method thereof
12/02/2009CN101591322A Cyclin dependent kinases inhibitor scutellaria flavonoid organic amine derivatives, preparation method and application thereof
12/02/2009CN101591321A Method for preparing 5,6,7,4'-tetrahydroxyflavone and application of 5,6,7,4'-tetrahydroxyflavone in medicaments
12/02/2009CN101591318A 3,5,7-trihydroxy flavone derivative, preparation method and application thereof
12/02/2009CN101591316A Homoisoflavone, dihydrohomoisoflavone and homoisoflavane derivatives and application thereof
12/02/2009CN101591315A Novel homoisoflavone compound and application thereof
12/02/2009CN101591314A Ophiobolin di-sesquiterpene compound and preparation method and application thereof
12/02/2009CN101591288A Cytochalasin compounds and preparation method and application thereof
12/02/2009CN101591280A Retinoids with effect of induction of differentiation of tumors and pharmaceutical composition as well as application thereof
12/02/2009CN101591230A 2,4-dyhydroxyl chalcone derivative, preparation method and application thereof
12/02/2009CN101590243A Application of small RNAs in preparing medicaments for treating and/or preventing lymphoma
12/02/2009CN101590242A Method for preparing chitosan or sodium alginate-modified carbon nanotube-targeted slow release carrier
12/02/2009CN101590229A Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
12/02/2009CN101590209A Medicament for treating tumors and preparation method thereof
12/02/2009CN101590200A Application of traditional Chinese medicine composition in preparing medicament for treating tumors
12/02/2009CN101590193A Traditional Chinese medicine combination for treating leukemia and preparation method thereof
12/02/2009CN101590186A Chinese medicinal composition for thoroughly eliminating hysteromyoma
12/02/2009CN101590176A Chinese medicinal preparation for treating esophagus cancer
12/02/2009CN101590172A Chinese medicament formulation for external application for treating cancer
12/02/2009CN101590170A Drug composition for treating cancer and preparation method thereof
12/02/2009CN101590158A Method for extracting polyphenol from canna edulis ker waste residue
12/02/2009CN101590151A Chinese medicament for curing bone covering tumor
12/02/2009CN101590103A Traditional Chinese medicine combination for treating leukemia and preparation method thereof
12/02/2009CN101590099A Addie micro-emulsion and preparation method thereof
12/02/2009CN101590092A Traditional Chinese medicine combination for treating leukemia and preparation method thereof
12/02/2009CN101590091A Traditional Chinese medicine combination for treating leukemia and preparation method thereof
12/02/2009CN101590078A Anticancer healthcare medicinal granules and production method thereof
12/02/2009CN101590060A Composition of ligustrazine and salvanolic acid B and application thereof
12/02/2009CN101590057A Antitumor compositions containing taxane derivatives
12/02/2009CN101590037A Andrographolidume composition and application thereof
12/02/2009CN101590035A Application of dehydrogenated silybin in preparing anti-lung-cancer medicament
12/02/2009CN101590018A Etoposide solid lipid nanoparticle and preparation method thereof
12/02/2009CN101590017A Method for preparing taxol magnetic nano liposome
12/02/2009CN101589801A Process for manufacturing red ginseng honey slice
12/02/2009CN101589799A Multi-nutrient breakfast
12/02/2009CN100564525C Prostate gland cancer cell specific promoter and its application
12/02/2009CN100564524C Factor involved in metastasis and uses thereof
12/02/2009CN100564517C Anti-glioma peptide of scorpion, preparation method and application thereof
12/02/2009CN100564380C Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors
12/02/2009CN100564377C Substituted 4H-chromenes and analogs as activators of caspase and inducers of apoptosis and use thereof
12/02/2009CN100564375C (3Z) -3-(2,3-dihydro-1H-ylidene)-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
12/02/2009CN100564365C Production of 1-[3,5-2(2,2-dimethyl) ethylcyano] benzyl triazole
12/02/2009CN100563716C Bio-compatible monodisperse nano polymer carrier and its preparation and medicine-carrying method
12/02/2009CN100563715C Taxdol self-assembled precursor liposome and its preparation method
12/02/2009CN100563712C Liquid formulations of tumor necrosis factor-binding proteins
12/02/2009CN100563711C Slow-released anticancer injection
12/02/2009CN100563710C Slow-released anticancer medicine preparation containing pyrimidine analog
12/02/2009CN100563709C Novel targeted tissue factor antibody as anticoagulants
12/02/2009CN100563707C Activation and inhibition of the immune system
12/02/2009CN100563646C Oxaliplatinum liposome glucose formulation preparation method
12/02/2009CN100563645C Beisalutin sustained-release implantation agent for curing entity tumour
12/02/2009CN100563644C Carmustine sustained-release implantation agent for curing entity tumour
12/01/2009US7626074 Method of screening candidate drugs for the treatment of leukemia
12/01/2009US7626031 5-[(1-Ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; antiproliferative agents; modulating cell differentiation,migration, and chemoinvasion; endothelial growth factor-modulated diseases; antiarthritic agents; graft versus host diseases
12/01/2009US7626026 Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
12/01/2009US7626019 Antiproliferative agents
12/01/2009US7626012 Nucleic acids encoding monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CD40; Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
12/01/2009US7625999 Immobilization on solid support
12/01/2009US7625937 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
12/01/2009US7625934 Metalloproteinase inhibitors
12/01/2009US7625919 Osteoporosis; oral diseases; bone disorders; atherosclerosis; antiarthritic agents; autoimmune disease; cachexia
12/01/2009US7625914 2(S)-Ethoxy-3-{4-[2-(3-heptyl-1-methylureido)thiazol-4-yl]phenyl}propanoic acid; dermatology, and cardiovascular diseases, immune diseases, lipid metabolism diseases; veterinary medicine
12/01/2009US7625913 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
12/01/2009US7625908 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
12/01/2009US7625895 e.g. 5-[rac-cis-2,3-Bis-(4-chloro-phenyl)-5-oxo-2,3-dihydro-5H-imidazo[1,2-a]pyridine-1-sulfonyl]-2-fluoro-benzonitrile; inhibit the interaction of tumor suppressor MDM2 protein with a p53-like peptide; antiproliferative agent; cycle arrest in G1 and G2 phase
12/01/2009US7625894 Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors
12/01/2009US7625892 Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/01/2009US7625890 Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
12/01/2009US7625883 Choline Salt of L- alpha -glycero-phospho-D-mio-inositol; alpha -glycero-phospho-D-mio-inositol tetrabutylammonium salt; treatment of pathologies mediated by the activation or over stimulation of cytololilc phospholipase-2 (PLA2), particularly, septic shock and viral and bacterial infections
12/01/2009US7625879 Phosphohalohydrins, process for the production thereof and use thereof
12/01/2009US7625860 Administering a combination of a cytotoxic agent and a fibroblastic growth factor antagonist, wherein the FGF antagonist enhances the efficacy of the cytotoxic agent
12/01/2009US7625859 HER-2 binding antagonists
12/01/2009US7625751 WNV core protein/capsid interacting protein and uses of the same
12/01/2009US7625713 Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide
12/01/2009US7625696 Method and screening kit using a GPR30 receptor and a ligand capable of specifically binding to receptor, a compound which is obtainable using screening method or kit; particularly relates to screening method and screening kit for prevention/treatment of cancer, heart disease
12/01/2009US7625573 Immunology active materials; anticancer agents, infections, autoimmune diseases, parasiticides; lipid bilayer with antitumor agent
12/01/2009US7625562 Generation of cartilage using magnetizable particles
12/01/2009US7625558 Anticancer agents; administering nucleic acid which dimerizes with protein
12/01/2009CA2461100C 4-imidazolin-2-one compounds
12/01/2009CA2407210C Liposome drug delivery
12/01/2009CA2265547C Method of treating endothelial injury
12/01/2009CA2154163C Ligand antagonists for treatment of breast cancer
12/01/2009CA2107513C Fusion protein for prodrug activation
11/2009
11/26/2009WO2009143515A2 Treatment using continuous low dose application of sugar analogs
11/26/2009WO2009143477A1 Heterocycles as protein kinase inhibitors
11/26/2009WO2009143454A2 Combination antitumor therapy
11/26/2009WO2009143372A2 Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
11/26/2009WO2009143371A2 COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
11/26/2009WO2009143317A1 Triazine compounds as p13 kinase and mtor inhibitors
11/26/2009WO2009143313A1 Triazine compounds as p13 kinase and mtor inhibitors